Bioventus Inc. (NASDAQ: BVS)

Bioventus Inc. is a global medical device company focused on helping patients recover and live life to the fullest by relieving pain and addressing musculoskeletal challenges through a diverse portfolio of high quality clinically proven solutions. The company manages its business through two reporting segments U. S. and International which accounted for 88% and 12% of total net sales during the fiscal year ended December 31 2025. Its product portfolio is organized into three businesses based on clinical use: Pain Treatments, Surgical Solutions and Restorative Therapies.

Bioventus generates revenue by selling its medical device products directly to healthcare providers and through distributors. Revenue comes from hyaluronic acid injections such as Durolane GELSYN 3 and SUPARTZ FX for knee osteoarthritis, peripheral nerve stimulation devices including StimRouter Talismann and StimTrial, the XCELL platelet rich plasma system, ultrasonic surgical platforms like neXus BoneScalpel SonaStar and SonicOne, bone graft substitutes such as OSTEOAMP SIGNAFUSE PUREBONE and Reficio DBM, and the EXOGEN ultrasound bone stimulation system. In the United States the company uses a direct sales force supported by an indirect team for Surgical Solutions while internationally it relies on a mix of direct indirect and distributor channels.

The company operates through the following segments: Pain Treatments, Surgical Solutions and Restorative Therapies.

• Pain Treatments: This segment offers intra articular hyaluronic acid injections for knee osteoarthritis, peripheral nerve stimulation devices for chronic pain, and the XCELL platelet rich plasma system for orthopedic and sports medicine applications.

• Surgical Solutions: This segment provides ultrasonic surgical platforms for precise bone and soft tissue resection, and a range of bone graft substitute products to promote spinal fusion and bone healing after surgery.

• Restorative Therapies: This segment delivers low intensity pulsed ultrasound systems to stimulate bone healing in non union and fresh fractures, primarily through the EXOGEN device.

Bioventus holds a competitive position in the medical device industry by leveraging a broad and diversified product line that addresses multiple pain and orthopedic needs. Key competitors in the Pain Treatments space include Ferring Pharmaceutical Inc., Fidia Farmaceutici S.p. A., Johnson & Johnson, Zimmer Biomet Holdings Inc., Arthrex Inc., Emcyte Corporation, and Channel Markers Medical while in peripheral nerve stimulation the company faces SPR Therapeutics, Nalu, and Curonix. In Surgical Solutions rivals are Medtronic, DePuy Orthopaedics (Johnson & Johnson), Stryker Corporation, NuVasive Inc., Orthofix Medical Inc., Zimmer Biomet Holdings Inc., Globus Medical Inc., Integra Life Sciences Inc., and Söring. Restorative Therapies competes with Orthofix Medical Inc., Zimmer Biomet Holdings Inc., Enovis, and XFT Medical. The company’s advantages stem from its clinically proven offerings, strong sales and marketing infrastructure, ongoing investment in emerging technologies, and regulatory clearances that support rapid product launches.

The company serves physicians, ambulatory surgical centers, hospitals, and other healthcare providers involved in orthopedic neurosurgical and general surgery procedures.